Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Continuation of natalizumab treatment reduces risk of MS relapses during pregnancy

Key clinical point: Continuing natalizumab treatment during pregnancy reduces the risk of relapse and does not increase risks to newborns.

Major finding: The annualized relapse rate among women who continued treatment after the first trimester was 0.09.

Study details: A comparison of two cohorts of women with multiple sclerosis who received treatment with natalizumab and became pregnant.

Disclosures: The authors received funding from companies such as Biogen, Merck Serono, and Teva.

Citation:

Landi D et al. ECTRIMS 2019, Abstract 338.